Keyphrases
Ovarian Cancer Patients
100%
Whole Exome Sequencing
100%
DNA Damage Response Genes
100%
DNA Damage Response Pathway
100%
Somatic Variants
100%
BRCA1, BRCA2
75%
Disease Progression
50%
PARP Inhibitor (PARPi)
50%
Serous Adenocarcinoma
50%
High-grade Serous
50%
Insertion-deletion
25%
Treatment Response
25%
Ovarian Cancer
25%
Clinical Trials
25%
Overall Survival
25%
Nucleotide Variants
25%
Tumor Protein p53 (TP53)
25%
Associated Genes
25%
Splice Site
25%
Clear Cell Carcinoma
25%
Inhibitor Treatment
25%
Sequence Data
25%
Unique Genes
25%
Exonic
25%
Variants of Uncertain Significance
25%
Platinum-based Chemotherapy
25%
Cancer Genome Atlas
25%
XRCC4
25%
Homologous Recombination Deficiency
25%
TP53 Variants
25%
RPA3
25%
Biochemistry, Genetics and Molecular Biology
DNA Damage Response
100%
Exome Sequencing
100%
BRCA1
50%
Poly ADP Ribose Polymerase
33%
Indel
16%
Clinical Trial
16%
Overall Survival
16%
Homologous Recombination
16%